Filip Matthijssens

Argenx (Belgium) — Belgium

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index3.0kcitations105works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(42), Acute Myeloid Leukemia Research(41), CAR-T cell therapy research(41), Acute Lymphoblastic Leukemia research(19), Genetics, Aging, and Longevity in Model Organisms(14)

Publications105 total

Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)
Blood·2025
Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)
Blood·2024· 1 citedOpen Access
Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia
Blood·2024· 2 cited
A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia
Science Advances·2024· 6 citedOpen Access
CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia
Haematologica·2023· 8 citedOpen Access
Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
Blood·2023· 1 citedOpen Access
P326: A DUAL ROLE FOR PSIP1 IN T-ALL
HemaSphere·2023Open Access
S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
HemaSphere·2023· 1 citedOpen Access
Supplementary Figure 7 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Data from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 3 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 15 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 8 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 4 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 6 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 16 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 9 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 10 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
Supplementary Figure 5 from Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Pieter Van Vlierberghe(25), Steven Goossens(15), Jacques R. Vanfleteren(14), Wouter Van Loocke(14), Bart P. Braeckman(13), Tom Taghon(12), Tim Pieters(12), Filip Van Nieuwerburgh(10), Sofie Peirs(9), Tim Lammens(9), Lindy Reunes(9), Barbara De Moerloose(8), Kaat Durinck(8), Geert Berx(8), Béatrice Lintermans(8), Patricia Back(7), Lisa Demoen(7), Dieter Deforce(7), Bruce Poppe(6), Juliette Roels(6)